YJYongliang Jia

Yongliang Jia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yongliang Jia has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Siu-Wai Leung

    Edinburgh Bayes Centre for AI Research in Shenzhen, College of Science and Engineering, University of Edinburgh, Scotland, UK

    10 shared publications
  • Siu-Wai Leung

    State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

    4 shared publications
  • Fangyi Huang

    3 shared publications
  • Hongmei Zhu

    The Center of Gastrointestinal and Minimally Invasive Surgery, Department of General Surgery, The Third People’s Hospital of Chengdu, Chengdu, Sichuan, People’s Republic of China

    3 shared publications
  • Hongmei Zhu

    Section for Gastrointestinal Surgery, Department of General Surgery, The Third People’s Hospital of Chengdu, Clinical College of Southwest Jiao Tong University, The Affiliated Hospital of Southwest Jiao Tong University, Chengdu, China

    3 shared publications
  • Siu-Wai Leung

    University of Macau

    3 shared publications

Latest Publications

  • Open Access

    Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives

    by Xiaonan Liang, Ping Jin, Yan Xue, Yongliang Jia, Hongmei Zhu, Guiyi Gong, Hua Zhou, Hao Hu, Simon Ming-Yuen Lee

    Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition with limited approved pharmacotherapies. Drug repurposing offers a time-efficient alternative to de novo development, yet existing reviews often compile candidate compounds without critically appraising the methodological robustness, evidence quality, or translational barriers. In this review, we evaluated current repurposing strategies, including real-world data analyses, computational screening, and experimental validations. As a preliminary search for this review, we searched PubMed and clinical trial registries up to October 2025 using predefined search terms related to MAFLD, drug repurposing, and clinical trials. Despite numerous computational predictions and preclinical candidates, only a small fraction have advanced to late-stage trials. To date, regulatory approvals for MAFLD remain limited, with only a few agents approved and even fewer through repurposing. We examine key obstacles to clinical success, including patient heterogeneity, lack of validated biomarkers, inconsistent endpoint selection, and limited mechanistic target validation. In addition, we discuss the integration of multi-omics and AI-driven approaches with phenotypic screening as a promising avenue for target identification and validation. Our findings suggest that successful repurposing in MAFLD may benefit from a shift toward evidence-based, mechanism-informed frameworks, supported by real-world evidence and adaptive trial designs. This review summarizes current evidence and identifies open questions that may guide future research and clinical development.

  • Open Access

    Clinical evidence of exercise intervention in improving adults with type 2 diabetes mellitus and frailty: a narrative literature review

    by Xiuli Mo, Zhengyu Duan, Weihong Zhang, Yongliang Jia

    Background: The global aging process is accelerating with the increasing prevalence of diabetes mellitus in the elderly population. Frailty, a clinical syndrome closely related to age, is particularly prevalent in elderly with type 2 diabetes mellitus (T2DM). Previous studies indicated that some common mechanisms and exercise interventions may be an effective intervention for T2DM and frailty management. Objective: This narrative literature review aimed to provide evidence to explore possible common mechanisms and the role of exercise in management of T2DM combined with frailty. Methods: PubMed was searched for mechanistic studies. PubMed and China National Knowledge Infrastructure were searched for randomized controlled trials (RCTs) exploring exercise for T2DM and frailty. Results: Mechanistic analysis on 33 studies identified overlapping pathophysiological pathways between T2DM and frailty including encompassing inflammaging, insulin resistance, β-cell dysfunction, mitochondrial impairment, and gut dysbiosis. Evidence synthesized from 20 RCTs demonstrates that multicomponent exercise interventions could reduce frailty, lower blood glucose levels, and improve muscle strength for patients with T2DM and frailty, potentially by modulating these shared pathways, and resistance training enhances insulin sensitivity and muscle synthesis via GLUT-4 upregulation and Akt/mTOR activation. Conclusion: Multicomponent exercise and resistance training would be efficacy for elderly patients with T2DM and frailty through modulating the overlapping pathophysiological mechanisms.

  • Open Access

    Efficacy and safety of AiDi injection in treating primary liver cancer: a systematic review on 70 randomized controlled trials

    by Zhengyu Duan, Xiuli Mo, Lanxu Jia, Haoyuan Li, Xiaonan Liang, Shuiling Jin, Yongliang Jia

    AiDi injection (ADI) has been widely used for primary liver cancer (PLC), and numerous clinical trials in China have been conducted to compare the efficacy of ADI with other treatments for PLC. This study aimed to conduct a systematic review and meta-analysis to comprehensively evaluate ADI for PLC. PubMed, Web of Science, the Cochrane Library, CNKI, and WanFang Database were searched to select randomized controlled trials (RCTs) that evaluated ADI for PLC, with outcomes including disease control rate (DCR), objective response rate (ORR), quality of life (QoL), and serious adverse events (SAEs). The RoB2 tool was used to assess RCTs. Meta-analysis based on a random-effects model computed the overall effect sizes using odds ratio (OR) with 95% confidence intervals (CIs). Subgroup and sensitivity analyses, meta-regression, and publication bias were also conducted. The strength of evidence was assessed using the GRADE method. This study included 70 RCTs involving 5283 PLC patients. The overall RoB of RCTs was assessed as having some concerns. The effect size of OR was 2.86 (95% CI [2.41, 3.40]) with statistical significance (P < 0.00001) for DCR. The OR demonstrated statistically significant effect sizes of 2.12 (95% CI [1.84, 2.45]; P < 0.00001), 3.89 (95% CI [3.08, 4.90]; P < 0.00001), and 0.21 (95% CI [0.12, 0.36]; P < 0.00001) for ORR, QoL, and SAEs, respectively. Moreover, subgroup and sensitivity analyses, and meta-regression analyses found consistent results. Most publication bias analyses showed insignificant differences. The strength of evidence was rated as moderate. ADI combination therapy demonstrated significant efficacy and safety in PLC patients. Nevertheless, further strong evidence through more high-quality RCTs is warranted to support these findings.

  • Open Access

    Heterogeneity and efficacy of immunotherapy in multiple cancer: insights from a meta-analysis

    by Weidong Wu, Bin Liu, Qing Zhang, Xiaojuan Zhang, Pengya Feng, Yongliang Jia, Xia Xue

    Immunotherapy has been recognized as a significant advancement in cancer treatment by promoting the body's immune system to identify and eliminate cancer cells more effectively. Unlike conventional therapies, immunotherapy can enhance the natural capabilities of human immune system. Chimeric Antigen Receptor T-cell (CAR-T) therapy involves genetical-modified T-cells from patients to better catch and attack cancer cells. Up to date, CAR-T therapy has shown particular promise in treating certain types of leukemia and lymphoma, highlighting the transformative potential of immunotherapy. Literature data search using PubMed, CNKI, and Wanfang were searched to collect eligible studies up to January 2025. The primary outcomes of complete response rate (CRR), objective response rate (ORR), dead rate (DR), and other adverse reactions were evaluated. Secondary outcomes (CRR, ORR, and DR) of subgroup analysis from different cancer types, origins, and outcomes for survival rate were analyzed for our final results. A total of 649 studies were initially identified through database searching. After removing duplicates and non-clinical cancer studies, 32 eligible studies were included in this work. The pooled data included 819 patients for objective response rate (ORR), 843 patients for complete response rate (CRR), and 868 patients for dead event. In the included studies, 24 reported ORR data, revealing an objective response rate of 84.86% (695/819) with little heterogeneity (OR: 0.87, 95% CI 0.80-0.91, P = < 0.01, I2 = 61%); 24 studies showed a CRR of 65.30% (491/843) with significant heterogeneity (OR: 0.58, 95% CI: 0.43-0.72, P < 0.01, I2 = 84%); 27 studies showed a mortality rate of 23.73% (206/868) with significant heterogeneity (OR: 0.19, 95% CI: 0.11-0.32, P < 0.01, I2 = 77%). Subgroup analysis based on cancer type revealed that ORR was higher in multiple myeloma (86.77%, 400/461) compared with leukemia (84.92%, 259/305) and lymphoma (67.92%, 36/53). In parallel, heterogeneity observed based on case origins suggested that Chinese cases showed significantly higher ORR, CRR, and survival rates compared with American ones. This meta-analysis provides valuable insights into the potential of immunotherapy, particularly CAR-T, in cancer treatment. Findings showed the different efficacy and safety of immunotherapy in treating multiple cancers, with various objective response rates. Continued studies from more trials with different populations are needed to optimize their efficacy in further cancer treatment and precision medicine.


  • Open Access

    Evidence map construction of acupuncture for type 2 diabetes mellitus and depression

    by Yongliang Jia, Xiaonan Liang, Hongmei Zhu, Lanxu Jia, Weihong Zhang

  • Open Access

    Potential mechanism of ginseng against frailty on network pharmacology and Bioinformatics analyses

    by Yongliang Jia, Xiaonan Liang, Hui Zhou, Hongmei Zhu, Weihong Zhang

  • Open Access

    Application and research progress of CAR-T cell therapy in autoimmune diseases

    by Xiaoxiao Yu, Haodong Shang, Xinru Shen, Jing Zhang, Ting Chang, Zhe Ruan, Yongliang Jia, Feng Gao

    The conventional clinical therapies for autoimmune diseases (ADs) lack specificity, necessitating long-term medication that can lead to serious side effects. In contrast, chimeric antigen receptor (CAR) T cell therapy for ADs, characterized by fewer side effects and longer-lasting therapeutic effects, represents a new direction for the specific treatment of ADs. T cells modified with CAR genes possess the ability to not only secrete perforin, granzymes, and other molecules that target autoreactive immune cells but also to lead effector and regulatory T cells into autoimmune environments, thereby exerting transport, proliferation, and immune regulatory functions. Chimeric autoantibody receptor T cells can recognize and kill autoreactive cells expressing target autoantibodies through their specific antigens. In this article, we comprehensively expound on the application of CAR-T cell therapy in different ADs and summarize the current research progress in this regard. This review aims to enhance the application of CAR-T therapy in AD treatment and facilitate further studies aimed at addressing the existing gaps in CAR-T therapy for ADs.


  • Open Access

    B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential

    by Haodong Shang, Xinru Shen, Xiaoxiao Yu, Jing Zhang, Yongliang Jia, Feng Gao

    Autoimmune encephalitis (AE) broadly refers to inflammation of the brain parenchyma mediated by autoimmune mechanisms. In most patients with AE, autoantibodies against neuronal cell surface antigens are produced by B-cells and induce neuronal dysfunction through various mechanisms, ultimately leading to disease progression. In recent years, B-cell targeted therapies, including monoclonal antibody (mAb) therapy and chimeric antigen receptor T-cell (CAR-T) therapy, have been widely used in autoimmune diseases. These therapies decrease autoantibody levels in patients and have shown favorable results. This review summarizes the mechanisms underlying these two B-cell targeted therapies and discusses their clinical applications and therapeutic potential in AE. Our research provides clinicians with more treatment options for AE patients whose conventional treatments are not effective.